Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase IIb dose-ranging induction trial.- InDEx Pharma and Merck KGaA
Read time: 1 mins
Last updated:26th Oct 2020
Published:23th Oct 2020
InDex Pharmaceuticals Holding AB (publ) announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology.
Condition: Ulcerative Colitis